Erasca Announces FDA Clearance of UCLA Developed Drug

UCLA Researchers David Nathanson, Ph.D., Michael Jung, Ph.D., and Timothy Cloughesy, M.D. developed ERAS-801, an orally available small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central nervous system (CNS) penetration for the treatment of recurrent glioblastoma multiforme (rGBM). The company Erasca licensed ERAS-801 from Katmai Pharmaceuticals, Inc. and received FDA clearance.

Read the release here